AGP Executive Report
Last update: 4 hours agoFDA & Vaccines: Moderna’s first mRNA flu vaccine for adults 50+ (mFlusiva) won FDA approval, adding a new option for seniors as flu hospitalizations stay high. Oncology Advances: MonumenTAL-6 data highlight a major risk reduction with teclistamab plus talquetamab in relapsed/refractory multiple myeloma, while FDA cleared Replimune (Tudriqev) with Opdivo for advanced melanoma after prior setbacks. Tech in Care: A small UC San Diego study found Apple Vision Pro could cut endoscopic tear-duct surgery time by about 19% and reduce surgeon workload. Policy & Access: CMS’s Medicaid work requirements rule sets a nationwide “community engagement” framework, but states will vary on exemptions and verification. Health Systems & Safety: Shared cardiac PET programs may expand access, and RFID tracking is being pitched to close hospital medication inventory gaps. Public Health Watch: Cyclospora investigations expanded across more states, with CDC-linked guidance urging caution with certain raw produce. Business Moves: Biogen completed its RayThera acquisition to bolster immunology assets.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[What Does an End-of-Life Doula Do for Patients With Cancer?]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27319931-932329466-a1cf18fa43dfd3521714f52f5cd06e6dc14ebc9c-1920x1080-200x113.png)
